Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer’s Disease at 2022 CTAD Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cognito Therapeutics, a clinical-stage company pioneering disease-modifying therapeutic interventions for neurodegenerative diseases, announced today it has been selected to present clinical data from its proprietary gamma sensory stimulation in patients with Alzheimer’s Disease, at the 2022 Clinical Trials in...

Alzheimer’s Association Western Gala | Lifestyle

Country United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico City, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People’s Socialist Republic ofAlgeria, People’s Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60...

New biomarker may aid early diagnosis

Share on PinterestResearchers have identified a new biomarker for hereditary Alzheimer’s disease. Image credit: Arturo Pena Romano Medina/Getty Images. Common symptoms of Alzheimer’s disease include memory loss, language problems, and impulsive or unpredictable behavior. However, the disease starts to develop long...

Alzheimer’s Association, state fire marshal offer virtual program on fire safety | News

Country United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico City, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People’s Socialist Republic ofAlgeria, People’s Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60...